Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome

Prolonged gastric mucosal haemorrhage following azacitidine administration in a patient with myelodysplastic syndrome

Bibliographic Details
Main Authors:	Hiroaki Kitamura, Koichi Miyahara, Yasushi Kubota, Rika Tomimasu, Shinya Kimura, Masaharu Miyahara
Format:	Article
Language:	English
Published:	Wiley 2021-08-01
Series:	eJHaem
Online Access:	https://doi.org/10.1002/jha2.206

Similar Items

The role of azacitidine in the management of myelodysplastic syndromes (MDS)
by: KS G&ouml;tze, et al.
Published: (2009-10-01)

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis
by: Ronit Gurion, et al.
Published: (2010-02-01)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
by: Konstantinos Liapis, et al.
Published: (2021-02-01)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
by: Ritchie EK
Published: (2012-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
by: I. Mandac Smoljanovic, et al.
Published: (2024-01-01)

MYELODYSPLASTIC SYNDROME RESPONDING TO THE AZACITIDINE PROTOCOL ASSOCIATED WITH HIGH DOSES OF VITAMINS
by: VM Sthel, et al.
Published: (2023-10-01)

A Case of Organizing Pneumonia Following Azacitidine Treatment for Myelodysplastic Syndrome
by: Kelly Ann Hutchinson, et al.
Published: (2023-05-01)

Late-onset Erythropoietic Protoporphyria Associated with Myelodysplastic Syndrome Treated with Azacitidine
by: Ai Yoshioka, et al.
Published: (2017-11-01)

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes
by: Unnikrishnan, A, et al.
Published: (2017)

Combination therapy with venetoclax and azacitidine for the treatment of myelodysplastic syndromes with DDX41 mutations
by: Xin Wang, et al.
Published: (2024-12-01)

A Case of Secondary Leukemia Subsequent to Myelodysplastic Syndromes Successfully Treated with Azacitidine
by: Takahiro Kumode, et al.
Published: (2014-01-01)

In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome
by: Francesco D’Alò, et al.
Published: (2021-04-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
by: Garcia-Manero, G, et al.
Published: (2021)

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
by: Tomáš Stopka, et al.
Published: (2022-07-01)

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - systematic review and meta-analysis (Reply to Kumar et al. and to Herbst et al.)
by: Ronit Gurion, et al.
Published: (2010-02-01)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
by: Andrius Žučenka, et al.
Published: (2023-08-01)

Female and preserved platelet count subgroups of myelodysplastic syndrome patients benefit from standard‐dose azacitidine
by: Shinichi Ogawa, et al.
Published: (2024-01-01)

Real-world effectiveness of azacitidine in treatment-naive patients with higher-risk myelodysplastic syndromes
by: Rajakumaraswamy, N, et al.
Published: (2023)

Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine
by: Kazuya Sato, et al.
Published: (2021-01-01)

Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis
by: Ambuj Kumar, et al.
Published: (2010-02-01)

Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients
by: Marguerite-Marie Le Pannérer, et al.
Published: (2022-11-01)

Azacitidine Omega-3 Self-Assemblies: Synthesis, Characterization, and Potent Applications for Myelodysplastic Syndromes
by: Milad Baroud, et al.
Published: (2021-12-01)

An Unexpected Innocent Complication Associated with Azacitidine Treatment of Myelodysplastic Syndrome: Erythema Annulare Centrifugum
by: Esra Turan Erkek, et al.
Published: (2016-02-01)

Dry Dressing for Epidermal Sloughing after Subcutaneous Azacitidine Injection in a Myelodysplastic Syndrome
by: Jun Yong Lee, et al.
Published: (2014-07-01)

BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by: Fernando Vieira Pericole, et al.
Published: (2019-01-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)

Long-term maintenance of the mucosal healing induced by azacitidine therapy in a patient with intestinal Behçet’s-like disease accompanied with myelodysplastic syndrome involving trisomy 8
by: Nahoko Tanaka, et al.
Published: (2019-11-01)

Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease
by: Koichi Murakami, et al.
Published: (2017-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
by: Garcia-Manero, G, et al.
Published: (2021)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
by: Ian M. Bouligny, et al.
Published: (2025-02-01)

Multiple myeloma with G‐CSF production mimicking chronic neutrophilic leukemia
by: Hiroshi Ureshino, et al.
Published: (2021-05-01)

Impact of the relative dose intensity on survival of patients with high‐risk myelodysplastic syndromes treated with Azacitidine
by: Kamel Laribi, et al.
Published: (2019-05-01)

INFECTIOUS COMPLICATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND CORRELATED MYELOID NEOPLASM TREATED WITH AZACITIDINE: AN UNICENTRIC COHORT
by: AFV Agreda, et al.
Published: (2024-10-01)

Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation
by: Nicolas Waespe, et al.
Published: (2016-12-01)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
by: Theodoros Karantanos, et al.
Published: (2022-12-01)